Our Company: Developing Oncology Therapeutics to Improve Cancer Care

Our lead therapeutic candidate, PCM-075, provides us the opportunity to bring a first-in-class PLK1 inhibitor to the market for the treatment of patients with acute myeloid leukemia (AML). The pharmacokinetic and pharmacodynamic properties of PCM-075 may provide a more selective approach for targeting the rapid mitosis that is characteristic of AML, as well as avoid some of the debilitating toxicities seen with standard chemotherapy drugs.

Highlights

Oncology Therapeutics, Precision Medicine in cancer - AML Ribbon
FDA approves IND for Phase 1b/2 trial of PCM-075 in patients with acute myeloid leukemia (AML)

PCM-075, in combination with decitabine, in patients with AML for exploration of the safety, tolerability, dose and scheduling, and antitumor activity.

  • Phase 1b is an open label dose escalation trial of PCM-075 in combination with decitabine to evaluate drug safety, tolerability, dose and scheduling, and determine a recommended clinical treatment dose for the Phase 2 continuation trial.
  • Phase 2 continuation trial is open-label with administration of the recommended PCM-075 clinical dose in combination with decitabine.
Oncology Therapeutics, Precision Medicine in cancer - NEXTCOLLECT Box
Coming Soon NextCollect

NextCollect is a first of its kind, proprietary urine collection and DNA preservation system. By housing the preservative solution in the reservoir cap, we have created the first ever automated DNA stabilizing device for urine collection. For more information, please email bd@trovagene.com.

Oncology Therapeutics, Precision Medicine in cancer - LD Micro
2017 Southern California Investor Conference

Trovagene CEO, Bill Welch, will be presenting at the conference on Thursday, August 24th, at 11:00 am PDT at The Island Hotel in Newport Beach, CA. The presentation will be webcast live at http://psevents.net/002/00271/2017-scic/?contid=track2 and a replay of the presentation will be available and archived for 90 days.